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ABSTRACT 
A small, diverse library of novel alkaloid-like compounds was synthesised using the bridged Ritter 
reaction with (–)-β-pinene and subsequent scaffold derivatisation. Structural diversity was achieved 
by varying the nitrile used in the reaction and thus provided an understanding of the influence 
nitriles have on the reaction outcome; it was determined that more nucleophilic nitriles, gave higher 
yields. Steric factors also determined the selectivity of scaffold types produced, with larger groups 
producing predominantly alkene products. X-ray crystallography and attempts to derivatise the 
imines obtained from the bridged Ritter reaction, highlighted the way the imino nitrogen reacted 
either not at all or in a stereospecific mannor, due to crowding by adjacent substituents. As the 
compounds contain either the 3-azabicyclo[3.3.1]nonane or 3-azabicyclo[3.3.1]non-3-ene core 
architecture, they will also be explored for their biological properties, due to the prevalence of 
bioactive alkaloids containing these core structures. 
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Alkaloids and their structurally similar synthetic counterparts are of keen interest in drug 
discovery due to the diverse range of biological activities reported.1,2 Although natural products play 
a significant role in the discovery of bioactive scaffolds, many alkaloids are rare and require complex 
isolation. These challenges are overcome by obtaining bioactive scaffolds through synthetic 
pathways. Our previous work has established the use of the bridged Ritter reaction of (–)-β-pinene 
to generate the 3-azabicyclo[3.3.1]non-3-ene architecture3 that mimics the core structure of the 


















(+)-aristolone (+)-aristoteline (–)-serratoline  
Fig. 1. Structures of Aristotelia alkaloids. 
Recently, we reported the synthesis of optically active 3-aza-bicyclic [3.3.1]non-3-ene cyclic 
imines via the bridged Ritter reaction.  These cyclic imines can be easily obtained in one single step 
from (–)-β-pinene and various nitriles, as shown in Scheme 1. This synthetic pathway is of significant 
interest as it provides optically pure products, with three stereocentres, in a one-pot reaction. It is 
well established that variation in the bridged Ritter reaction conditions, varies the reaction outcome5 
and, therefore, attempts to optimise the conditions to control the ratio of these products were also 







Scheme 1. The bridged Ritter reaction between (–)-β-pinene and nitriles. 
As part of our alkaloid-like drug discovery programme, we aim to develop feasible synthetic 
pathways that allow quick access to alkaloid-like chemical scaffolds which can be used to produce a 
library of alkaloid-like compounds for drug discovery. In this paper, we describe the detailed 
stereospecific synthesis of chiral 3-azabicyclo[3.3.1]non-3-enes via the bridged Ritter reaction, 
starting from (–)-β-pinene with various nitriles. We further explore the selectivity of the product 
outcome under different reaction conditions and some derivatisation is explored in order to add 
useful diversity to the library to understand the structure activity relationship (SAR) properties of the 
alkaloid-like compounds. 
2. Results and discussion 
2.1 Preparation of 6-N-amides, 6-alkene and 6-alcohols with 3-azabicyclo[3.3.1]non-3-ene core 
structure 
The cyclic imines (+)-1a, (+)-2a, (+)-1d, (+)-2d, (+)-1e, (+)-2e and 3e were previously prepared 
in our laboratory as the key chemical scaffolds for generating alkaloid-like compounds.3 The general 
scheme for the preparation of optically active imino amides (+)-1, imino alkenes (+)-2 and imino 
alcohols (+)-3, from (–)-β-pinene with various nitriles, via one-step bridged Ritter reaction is shown 
in Scheme 1. The reaction outcomes are summarised in Table 1. 

















Entry Nitrile -R Product/s (% Yield) 
a Acetonitrilea -CH3 (+)-1a (64), (+)-2a (23), (+)-5a (9) 
b Propionitrile -CH2CH3 (+)-1b (25), (–)-2b (14), (+)-5b (4) 
c Valeronitrile -CH2CH2CH2 CH3 (+)-1c (12), (+)-2c (12) 
d Chloroacetonitrilea -CH2Cl (+)-1d (31), (+)-2d (23) 







h Methyl cyanoacetate 
 
(–)-2h (2) 
i Ethyl cyanoacetate 
 









l Succinonitrile -CH2CH2CN (–)-2l (7) 
a results from nitriles previously published.3 
b 
4 results from  rearrangement of the cyanoacetate precursor imine 3, see section 2.2.2. 
c 8 results from the autoxidation of the precursor alkene 2, see section 2.2.1. 
 
2.2 Influence of the nitriles 
Table 1 summarises the yields of the corresponding products from each nitrile. The results of 
our early work with acetonitrile (a) and benzonitrile (e) revealed the formation of (+)-1 and (+)-2 in 
the ratios of 2.78:1 and 1.75:1, respectively.3 From the results reported herein, there is a clear trend 

















factor, the bulky nitriles tending to favour the formation of only imine-alkenes (+)-2. However, when 
benzonitrile was used, despite its relative bulkiness, it provided both (+)-1 and (+)-2. This suggests 
that the nucleophilicity of the nitriles has a strong influence on the selectivity of these cyclic imines.6 
Attack of the C-6 carbocation intermediate E by a strongly nucleophilic nitrile would eventually 
favour the formation of the imine-amides (+)-1 (Scheme 2), as previously reported.7 Where the 
imino-amides (+)-1 are the major product, the data suggest that the transformation of E into F is 
controlled by the rate k1, which is influenced by the nucleophilicity of the nitrile, and eventually 
forms (+)-1 upon quenching with water. The following explains some of the other interesting 
outcomes that resulted from the nitrile used. 
 
Scheme 2. Proposed mechanism for the bridged Ritter reaction with (–)-β-pinene. 
2.2.1 Oxidation of Benzylic products 
The reaction of benzyl cyanides (entry j and k) with (–)-β-pinene, yielded the oxidised 
product (–)-8j-k (Scheme 3). The oxidation of benzylic CH2 is well established in the literature, and it 
has also been reported that the use of benzyl cyanides under Ritter reaction conditions give 
products that underwent spontaneous oxidation to give benzoyl products.8 Initial evidence for the 
formation of (–)-8j was derived from its molecular weight observed in the crude GC/MS analysis, 
which showed a product fourteen mass units higher than that of the expected corresponding imine-
alkene, 2j. The IR spectrum presented a band at 1665 cm-1, corresponding to a conjugated ketone 
carbonyl group. It was further confirmed by the 13C NMR, in which the spectrum of (–)-8j showed a 

















Compound 2k was also initially noted in the crude mixture where GC/MS showed the m/z of 
298 for the non-oxidised product at 8.48 min while the oxidised product was m/z 312 at 8.43 min. 
Overtime, 2k underwent air oxidation at the benzylic carbon (C-4α) to provide (–)-8k as observed in 
1H NMR by the disappearance of the benzylic protons signal at (3.71 ppm). IR spectroscopy indicates 
the presence of the ketone carbonyl stretch at 1672 cm-1. Due to this oxidation, only the benzoyl 
products (–)-8j and (–)-8k were able to be isolated and fully characterised. 
2j: R = Br
2k: R = NO2
[O]
(–)-8j: R = Br
(–)-8k: R = NO2  
Scheme 3. Autoxidation of benzylic products. 
2.2.2 Cyanoacetate rearrangement  
Two cyanoacetate nitriles were used with the bridged Ritter reaction, methyl and ethyl- 
cyanoacetate (entry h and i). The products obtained from these nitriles were low yielding; (–)-2i was 
obtained with 7 % yield after isolation by preparative TLC, while (–)-2h was obtained with 2 % yield 
after column chromatography. Both of these alkenes exist in both the keto and enol form in solution 
(Scheme 4), as shown by the additional resonances in the NMR spectra. In the 1H NMR spectrum of 
(–)-2i, the OH and 4α-CH resonances of the enol form could be seen at 8.28 and 4.38 ppm 
respectively, while the 4α-CH2 of the keto-form occur as singlets at 4.73 and 4.63 ppm. In the 
13C 
NMR spectrum, the enol 4α-CH is observed at 80.00 ppm while the keto 4α-CH2 is observed at 
108.18 ppm. The same was observed for (–)-2h as shown in the experimental data. Using the 
integral values of the 1H NMR resonances, it was determined that the ratio of enol to keto for both 
(–)-2i and (–)-2h is 1:2. 
4α
enol-form
(–)-2h R = CH3
(–)-2i R = CH2CH3
4α
keto-form
(–)-2h R = CH3
(–)-2i R = CH2CH3  
Scheme 4. Interconversion of the enol and keto forms of (–)-2h and (–)-2i. 
The ethyl cyanoacetate also resulted in an unexpected amino-alcohol product (–)-4i; isolated 
in the β-unsaturated carbonyl (keto) form, as a result of imine-enamine tautomerisation. The X-ray 
structure was obtained from suitable single crystals of (–)-4i which were formed in the crude 
product and re-grown from CH2Cl2/hexane. The X-ray structure also shows that the C4 to C4α double 

















between NH---O=C (Fig. 2). The structure of (–)-4i was also confirmed spectroscopically, 
characteristic absorbance peaks were also observed in the IR spectrum, notably those corresponding 
to the alcohol, amine and carbonyl functionality stretches at 3470, 3287 and 1625 cm-1 respectively. 
 
Fig. 2. ORTEP diagram of a (–)-4i molecule in the crystal structure of racemic 4i, showing the 
intramolecular H-bonding between NH---O=C. 
The crystal structure of 4i was found to be in the Cc space group, having four symmetry 
operations, as this crystal contains the (–)-4i (1R, 5S, 8S) and (+)-4i (1S, 5R, 8R) enantiomers (Fig. 3). 
(–)-4i and (+)-4i are coloured in grey and magenta, respectively, according to their symmetry 
operation. This result was unexpected, as the bridged Ritter reaction is asymmetric and should 
generate optically pure products from chiral starting materials such as (–)-β-pinene.  
The presence of both enantiomers in the crystal packing was a result of trace impurities of 
(+)-β-pinene in the starting material. The (–)-β-pinene used for the reaction was sourced from 
Sigma-Aldrich, who reported that the product has a 97 % enantiomeric excess and a specific rotation 
of α
  22 (neat). We measured the optical rotation of the product to be α
 - 18.85 (neat). The 
trace amounts of (+)-4i in the crude product would have favoured the co-crystallisation of the 
enantiomers in the sample taken from the crude and recrystallised, while the purified sample of (–)-


















Fig. 3. Enantiomers of (–)-4i (grey) and (+)-4i (magenta, glide plane related) in the unit cell looking 
down the a axis. 
 2.3 Optimisation of bridged Ritter reaction conditions 
Christol9 stated that the use of polar solvents increased yields by increasing the 
nucleophilicity of the nitrile. There are several alternative catalysts for the generation of 
carbocations reported,10 however our investigation focused only on the use of concentrated sulfuric 
acid and the use of acetic acid as a polar solvent in replacement of benzene used in the standard 
conditions listed in the experimental section. These polar conditions were used with acetonitrile and 
propionitrile and resulted in the formation of additional acetate products (+)-5a and (+)-5b, as seen 
in Scheme 5, however did not result in an increased yield. Formation of the acetate products 
resulted from the nucleophilic addition of the acetate ion, to the carbocation generated at C-6 as per 
suggested mechanism shown in Scheme 2. 
5a: R = CH3














Scheme 5. Formation of acetate products (+)-5a and (+)-5b under polar bridged Ritter reaction 
conditions. 
 
The duration of reaction time was also found to influence the product ratio between the 
imino-amide and imino-alkene for acetonitrile. Under the standard reaction time, the reaction gave 

















hours, only the amide was formed. On the other hand, when the reaction time was extended to 96 
hours, the ratio became 1:3. It appears that the longer reaction times led to higher yields of the 
alkene product. This would indicate that in the suggested mechanism (Scheme 2), the reaction of E 
to F is an equilibrium process or that after the maximum amount of F has formed, the remaining 
carbocation E collapses slowly to the alkene. 
2.4 Reduction of cyclic imines 
Both imino-amide (Scheme 6) and imino-alkene (Scheme 7) products prepared via the 
bridged Ritter reaction have been reduced to the corresponding amino structures, using NaBH4.
12 
The imine bond of the imino-amides is reduced asymmetrically to give (R)-stereocentres exclusively 
at C-4, with the substituent from the nitrile projecting forward from the Re face, as depicted in 
Scheme 6. This stereoselective outcome resulted from the imino bond being hindered by the 
cyclohexane ring that projects out from the Re face of the imine, only allowing for the hydride ion to 
approach from the Si face side. The amino compounds retain their optical activity, as indicated by 
the reported optical rotations. 
(R)
a: R = CH3 (97%)
b: R = CH3 (42%)
c: R = CH3 (82%)
d: R = CH2Cl (88%)





Scheme 6. Reduction of imino-amide scaffolds to amino amides. 
Reduction of the imino-alkene (+)-2a resulted in a mixture of diastereoisomers, however, 
this non-facial selectivity of the hydride attack at C-4 was observed only when the -R group was 
methyl. In this case, the (R)-diastereoisomer (–)-7a was the major product and the only 
diastereoisomer isolated. The presence of the (S)-diastereoisomer was observed in the GC/MS and 
NMR analysis of the crude product, in which the ratio between (R) and (S) is 4.5:1, with GC retention 
times of 11.1 and 10.7 minutes, respectively. Table 2 lists the corresponding amino-amides (5) and 
amino-alkenes (6) that were obtained stereospecifically, containing (R)-stereocentres at the C-4 
position, via hydride reduction using NaBH4. 
(S)-7
a: R = CH3 (56%)
d: R = CH2Cl (85%)







Scheme 7. Reduction of imino alkene scaffolds to amino alkenes. 
Table 2. Yields of amine-scaffolds obtained from the reduction of corresponding imines. 
Entry Imine Used Amine Product Yield (%) 
1 (+)-1a (+)-6a 97 

















3 (+)-1b (+)-6b 42 
4 (+)-1c (+)-6c 82 
5 (+)-1d (+)-6d 88 
6 (+)-2d (–)-7d 85 
7 (+)-1e (+)-6e 94 
8 (+)-2e (–)-7e 80 
 
The stereochemistry at C-4 was confirmed by 1D NOESY experiments, where the orientation 
of H-4 was determined by observing the NOE (Nuclear Overhauser Effect) when irradiated. Cross-
peaks are seen between the H-4 and H-5 signals and the H-4 and CH3-2α signals, indicating their 
proximity of less than 3 Å and confirming that H-4 and H-5 are in the syn orientation. The spectral 
analysis of (+)-6a and (+)-6b and their respective X-ray structures (of single crystals grown from 
CH2Cl2/hexane), unequivocally confirm that C-4 is the (R)-stereocentre, with the hydrogen projecting 
away from the Re face of the ring and the substituent forward (Fig. 4). 
 
Fig. 4. ORTEP diagram of (+)-6a (left) and (+)-6b (right), showing the configuration of stereocentre at 
C-4. 
2.4.1 Crystal packing of (+)-6a and (+)-6b 
The X-ray analysis of compounds (+)-6a and (+)-6b revealed a remarkable similarity in the 
interactions involved in the packing of the molecules in crystals. Between the 21 screw related 
molecules, intermolecular hydrogen bonding was observed between the NH and C=O functionality of 
the amide groups at position 6 (N1-H1∙∙∙O1) and two C-H∙∙∙O contacts (one inter and one intra) 
between C=O and CH of either the amide CH3 for (+)-6a or CH2 for (+)-6b (Fig. 5 (a) and (b) 

















4. It should be noted that no hydrogen bonding is observed from the amine NH (N3-H3), this can be 
accounted for by the fact that the methyl substituents on the adjacent carbons are crowding the 
nitrogen and hindering any possible interactions. This can clearly be seen in the space filling 
diagrams for (+)-6a and (+)-6b in Fig. 6. 
Table 3. Hydrogen-bond geometry (Å, ᵒ) for (+)-6a 
D—H···A D—H H···A D···A D—H···A 
N1—H1∙∙∙O1’ 0.88 2.13 2.973 (4) 161 
C5—H5∙∙∙O1 1.00 2.43 3.105 (5) 125 
C16—H16B∙∙∙O1’ 0.99 2.37 3.280 (5) 152 
 
Symmetry codes: (i) −x+2, y+1/2, −z+3 
Table 4. Hydrogen-bond geometry (Å, ᵒ) for (+)-6b 
D—H···A D—H H···A D···A D—H···A 
N1—H1∙∙∙O1’ 0.81 (3) 2.22 (2) 3.0097 (18) 166 (2) 
C5—H5∙∙∙O1 0.98 (2) 2.45 (2) 3.1140 (18) 124.8 (17) 
C15—H15B∙∙∙O1’ 0.97 (3) 2.55 (3) 3.414 (2) 147.9 (19) 
 
Symmetry codes: (i) −x+1, y−1/2, −z+1. 
    
 
Fig. 5. The NH----O=C and CH---O=C hydrogen bonding observed in the crystal structures of a, 


















Fig. 6 Space filling diagrams of (+)-6a and (+)-6b, showing the crowding of the amine NH. 
2.5 Derivatisation imino and amino-amides 
2.5.1 Amide deprotection of 5d 
The diamine (+)-9d was obtained in one step from the amino-amide (+)-6d, via amide 
deprotection (Scheme 8). The presence of the chloroacetamide functional group in (+)-6d makes the 
amide bond labile, allowing it to be hydrolysed under mild conditions to (+)-9d. The reaction was 
performed according to the method outlined by Torres et al.,13 to give the diamine product (+)-9d. 
This primary amine introduces another viable point for further derivatisation and expansion of the 
















Scheme 8. Amide deprotection of amino amide (+)-6d to diamine (+)-9d. 
2.5.2 Reductive N-alkylation 
Reductive N-methylation was carried out on (+)-6a, using the method described by Taylor et 
al.,12 as shown in Scheme 9, which gave (+)-10a in 45 % yield. The reaction was also attempted under 
the same reaction conditions with propanal, pentanal and benzaldehyde, however, none of these 
reactions were successful and only starting material was recovered. The outcome of these attempts 
highlights the significance of the crowding of the amine at position NH-3 in the scaffold, as 
contributed by the three adjacent methyl groups, illustrated in the X-ray structures (Fig. 4). The 
hindered nature of NH-3 prevented access of the aldehydes and hence only formaldehyde could 
successfully react with (+)-6a to give (+)-10a. The identity of compound (+)-10a was confirmed by 






















Scheme 9. Reductive N-methylation of amino amide (+)-6a to (+)-10a. 
2.5.3 Reaction of 1a with dimethyl acetylenedicarboxylate 
The reaction of compound (+)-1a with dimethyl acetylenedicarboxylate (DMAD) was 
performed by adapting the method published by Ung et al.14 to afford (–)-11 in 57 % yield. The 
identity of compound (–)-11 was confirmed by the following; the 1H NMR spectrum showed new 
peaks corresponding to functionality added to the scaffold through the amine nitrogen at N-3. These 
include the singlet at 5.58 ppm due to the alkene C-H (C=CHCO2Me) and two new CH3 signals as 
singlets at 3.73 and 3.70 ppm corresponding to the two methoxy groups. The C-4 CH3 singlet has 
been lost and replaced by two singlets for each of the C-4 CH2 protons; these occur at 4.61 and 4.44 
ppm. 13C NMR spectrum reveals the new carbonyl carbons at 167.1 and 166.4 ppm as well as the 
new N-3α quaternary carbon at 146.8 ppm. The orientation of the two CO2Me groups were 
confirmed with 1D NOESY experiments. Upon irradiating the proton (C=CHCO2Me) at 5.58 ppm, two 
cross-peaks with the two CH3 groups (1.45 and 1.39 ppm) at C-2 (Figure 2.7) were observed. These 
indicate that they are within proximity of 3 Å to each other in space, and the two CO2Me group must 







Scheme 10. The reaction of (+)-1a with DMAD to give (–)-11. 
It was expected that compound (–)-11 could be cyclised through the C-4 CH2 and the imine 
as previously reported by Lin et al..15 However, this intermediate adduct product was unable to 
cyclise due to the highly hindered nature of the imine, as outlined in sections 2.4.1. Even the 
adsorption of (–)-11 to silica gel did not result in cyclisation, as reported in a follow up paper by Lin 
et al.,16 on the reactivity of the adduct. It is likely that for the tri-cyclic scaffolds previously reported 
by Lin et al., the imine nitrogen is relatively less hindered due to the constraints of the ring pulling 


















In summary, the bridged Ritter reaction is a viable method for generating a chemically 
diverse library of optically pure alkaloid-like molecules. The nitriles used have the greatest influence 
on the outcome of the reaction and scaffold type obtained, as well as providing a versatile range of 
functional group derivatives containing the 3-azabicyclo[3.3.1]non-3-ene core. Most notably, the 
more electron donating the nature of the group adjacent to the nitrile, the higher the yield. The 
increase in nucleophilicity of the nitrile favours the affinity towards the carbocation reaction 
intermediate, generating amides. However, as the size of the nitrile increases (for nitriles larger than 
benzonitrile), steric hindrance tends to favour the formation of the alkene product. The 
conformation of the scaffold must also provide a hindering steric effect in decreasing the nitriles 
ability to attack the carbocation.  
Reduction of the imine allowed secondary and tertiary amines to be generated. However, 
the hindered nature of these amines only allowed for alkylation with formaldehyde. The hindrance 
resulting from the crowding of the position 3 nitrogen is also observed in the X-ray crystal structures. 
It was found that the alkene product is extremely stable towards electrophilic addition and therefore 
is not a suitable functional group for derivatisation. Chloroacetonitrile, however, did provide a labile 
amide which was readily hydrolysed to give the amine functionality at C-6, which could be further 
functionalised. 
Initial biological screening of several compounds reported have shown anti-cancer activity, 
however, screening is yet to be completed on the full library and will be reported in the future. 
4. Experimental 
4.1 General  
Reagents and analytical grade solvents were purchased from commercial sources. The 
progress of reactions was monitored by TLC analysis, performed on aluminium backed Merck 60 
GF254 silica gel or Merck 60 GF254 neutral alumina gel with UV detection at 254 nm, I2 atmosphere. 
Compounds were purified by column chromatography using Merck flash either neutral alumina or 
silica gel (40 – 63 µm). The purity of compounds was determined by 1H NMR and GC/MS. 1H and 13C 
NMR spectra were recorded on an Agilent 500 MHz spectrometer (500 MHz 1H, 125 MHz 13C) in 
deuterated chloroform (CDCl3) unless otherwise specified. NMR assignments were based on COSY, 
HSQC and DEPT experiments. 1H and 13C NMR assignments are based on the numbering system used 
for the systematic name. Compounds 2h and 2i were observed in the NMR as tautomers, thus the 
NMR assignment reflects this. Low-resolution mass spectra were obtained on an Agilent 6890GC 
fitted with 5 % polysilphenylene, 95 % polydimethylsiloxane column and an Agilent 5973n MS (EI) 
spectrometer. High-resolution mass spectra were obtained on an Agilent 6510 Accurate-Mass Q-TOF 
Mass Spectrometer, equipped with an ESI source. Melting points were measured on a Gallenkamp 
Melting Point Apparatus equipment and were uncorrected. Optical rotation was measured using a 
Jasco P-2000 polarimeter. 
4.2 General procedures 

















 Sulfuric acid (18 M, 2 mL) was stirred in a flask fitted with a reflux condenser and a drying 
tube at 0 °C. To the reaction flask, the nitrile (53.4 mmol, 7 mol equiv. of (–)-β-pinene) was added. A 
solution of (–)-β-pinene (1.2 mL, 7.62 mmol) in benzene (5 mL) was added dropwise to the reaction 
mixture, via the condenser. A further 0.50 mL of benzene was used to wash all traces of (–)-β-pinene 
into the reaction flask. After 30 min the reaction was allowed to reach room temperature and left to 
stir for 24 h. The reaction was then quenched by the addition of water (30 mL). The mixture was 
then basified with 4 M NaOH (until pH > 10). The reaction mix was then extracted with CHCl3 (2 X 15 
mL) and dried with Na2CO3. Note: if the nitrile used was solid, it is dissolved in 20 mL benzene before 
addition to sulfuric acid. 
 
4.1.1 N-(4-Ethyl-2,2,6-trimethyl-3-azabicyclo[3.3.1]non-3-en-6-yl)propanamideI 1b  
(512 mg, 1.94 mmol, 25 %) as a white solid; m.p. 96-97 °C, Rf (ethyl acetate) 0.69; α]
	 +125.95 (c 
0.95, CHCl3); νmax(neat) 3278, 3080, 2972, 2946, 2872, 1637, 1555, 1451, 1348, 1285, 1235, 1110, 
955 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.35 (br s, NH), 3.27 (br s, 1H, CH-5), 2.31 (dt, J = 7.5, 6.0 Hz, 
1H, CH2-4α), 2.27 (dt, J = 7.5, 6.0 Hz, 1H, CH2-4β), 2.21 (qt, J = 7.5, 2.0 Hz, 2H, COCH2CH3), 1.80-1.83 
(m, 1H, CH2-9a), 1.76 (dt, J = 13.0, 2.0 Hz, 1H, CH2-8a), 1.66-1.63 (m, 2H, CH2-8b & CH-1), 1.56 (tt, J = 
13.5, 4.5 Hz, 1H, CH2-9b), 1.46-1.36 (m, 2H, CH2-7), 1.42 (br s, 3H, CH3-6α), 1.28 (br s, 3H, CH3-2α), 
1.16 (t, J = 7.5 Hz, 3H, COCH2CH3), 1.12 (br s, 3H, CH3-2α), 1.09 (t, J = 7.5 Hz, 3H, CH3-4β);
 13C NMR 
(125 MHz, CDCl3) δ 173.7 (C-4), 171.7 (C=O), 58.1 (C-6), 56.0 (C-2), 38.3 (CH-5), 36.7 (CH2-4α), 34.5 
(CH-1), 33.6 (CH2-7), 32.1 (CH3-2α), 31.0 (COCH2CH3), 27.4 (CH3-6α), 26.3 (CH3-2α), 25.1 (CH2-9), 24.9 
(CH2-8), 13.0 (CH3-4β), 12.3 (COCH2CH3); GC/MS Rt = 18.74 min, m/z 264 (72M), 249 (27), 191 (59), 
176 (50), 164 (56), 150 (47), 136 (100), 122 (23), 97 (31), 57 (33 %). HRMS (ES): C16H28N2O calcd: 
265.2275 [M+H]+; found: 265.2271 [M+H]+. 
4.1.2 4-Ethyl-2,2,6-trimethyl-3-azabicyclo[3.3.1]nona-3,6-diene 2b 
(198 mg, 1.04 mmol, 14 %) as a yellow oil; Rf (1:4 hexane/diethyl ether) 0.6; [α]

 –22.56 (c 1.00, 
CHCl3); νmax(neat) 2961, 2927, 2868, 1686, 1662, 1453, 1377, 1356 cm
-1; 1H NMR (500 MHz , CDCl3) δ 
5.34 (br s, 1H, CH-7), 2.60 (br s, 1H, CH-5), 2.27 (q, J = 7.5 Hz, 2H, CH2-4α), 2.25-2.14 (m, 2H, CH2-9), 
1.87 (br s, 1H, CH-1), 1.79-1.77 (m, 4H, CH3-6α & CH2-8a), 1.57 (dt, J = 12.0, 2.5 Hz, 1H, CH2-8b), 1.19 
(br s, 3H, CH3-2α), 1.16 (br s, 3H, CH3-2α), 1.11 (t, J = 7.5 Hz, 3H, CH3-4β); 
13C NMR (125 MHz, CDCl3) δ 
171.3 (C-4), 135.1 (C-6), 122.5 (CH-7), 58.7 (C-2), 38.5 (CH-5), 34.5 (CH2-4α), 34.10 (CH-1), 32.2 (CH3-
2α), 29.2 (CH2-9), 28.2 CH3-2α), 26.2 (CH2-8), 24.2 (CH3-6α), 11.9 (CH3-4β); GC/MS Rt = 5.431 min, m/z 
191 (14 M), 176 (5), 136 (23), 121 (11), 93 (100), 77 (14 %). HRMS (ES): C13H21N calcd: 192.1747 
[M+H]+; found: 192.1751 [M+H]+. 
4.1.3 N-(4-Butyl-2,2,6-trimethyl-3-azabicyclo[3.3.1]non-3-en-6-yl)pentanamide 1c 
(298 mg, 0.931 mmol, 12 %) as a yellow oil; Rf (1:3 ethyl acetate/hexane) 0.47; [α]
 +81.82 (c 1.35, 
CHCl3); νmax(neat) 3296, 3071, 2959, 2933, 2874, 1642, 1544, 1458, 1378, 1367, 1272, 1110, 929, 
910, 734 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.31 (s, 1H, NH), 3.27 (br s, 1H, CH-5), 2.32-2.28 (m, 1H, 
CH2-6αc), 2.25-2.20 (m, 1H, CH2-6αc), 2.17 (td, J = 7.5, 3.5 Hz, 2H, CH2-6αb), 1.84-1.79 (m, 1H, CH2-
8a), 1.75 (dt, J = 10.0, 13.0 Hz, 1H, CH2-9a), 1.75-1.65 (m, 1H, CH2-9b), 1.63-1.60 (m, 3H, CH-1 & CH2-
4αa), 1.59-1.52 (m, 2H, CH2-7a & CH2-8b), 1.45-1.30 (m, 7H, CH2-7b, CH2-4αb, CH2-4αc & CH2-6αd), 

















4αd), 0.90 (t, J = 7.5 Hz, 3H, CH3-6αd); 
13C NMR (125 MHz, CDCl3) δ 173.1 (C-4), 170.9 (C=O), 58.2 (C-
6), 56.1 (C-2), 42.7 (CH2-6αc), 38.7 (CH-5), 37.8 (CH2-6αb), 34.5 (CH-1), 33.5 (CH2-4αb), 32.1 (CH2-6α), 
31.2 (CH2-7), 28.2 (CH2-4αa), 27.4 (CH3-2α), 25.1 (CH2-8), 24.7 (CH2-9), 23.0 (CH2-6αd), 22.7 (CH2-
4αc), 14.4 (CH3-6αd), 14.2 (CH3-4αd); GC/MS Rt = 21.95 min, m/z 320 (1 M), 305 (6), 278 (27), 219 
(17), 177 (100), 57 (18 %). HRMS (ES): C20H36N2O calcd: 321.2900 [M+H]
+; found: 321.2884 [M+H]+. 
 
4.1.4 4-Butyl-2,2,6-trimethyl-3-azabicyclo[3.3.1]nona-3,6-diene 2c 
(198 mg, 0.903 mmol, 12 %) as a yellow oil; Rf (1:3 ethyl acetate/hexane) 0.97; α]
 +9.22 (c 1.00, 
CHCl3); νmax(neat) 2959, 2931, 2874,1698, 1655, 1560, 1542, 1458, 1382, 1361, 1331, 1255, 1207, 
1173, 980, 804 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.34 (br s, 1H, CH-7), 2.59 (br s, 1H, H-5), 2.29-2.26 
(m, 2H, CH2-4αa), 2.25-2.16 (m, 2H, CH2-8), 1.86 (br s, 1H, H-1), 1.80 (br s, 3H, CH3-6α), 1.78-1.75 (m, 
1H, CH2-9a), 1.57 (dt, J = 3.0, 12.0 Hz, 1H, CH2-9b), 1.52-1.48 (m, 2H, CH2-4αb), 1.37-1.32 (m, 2H, CH2-
4αc), 1.19 (br s, 3H, CH3-2α), 1.16 (br s, 3H, CH3-2α), 0.93 (t, J = 7.0 Hz, 3H, CH3-4αd); 
13C NMR (125 
MHz, CDCl3) δ 170.6 (C-4), 135.1 (C-6), 122.5 (CH-7), 58.7 (C-2), 41.3 (CH2-4αa), 38.7 (CH-5), 34.1 (CH-
1), 29.0 (CH3-2α), 29.8 (CH2-4αb), 29.3 (CH2-8), 28.1 (CH3-2α), 26.1 (CH2-9), 24.2 (CH3-6α), 23.0 (CH2-
4αc), 14.4 (CH3-4αd); GC/MS Rt = 14.26 min, m/z 219 (3 M), 204 (3), 190 (4), 177 (31), 162 (8), 136 
(9), 121 (9), 93 (100), 77 (12), 41 (12 %). HRMS (ES): C15H25N calcd: 220.2060 [M+H]
+; found: 
220.2048 [M+H]+. 
4.1.5 3-(2,2,6-Trimethyl-3-azabicyclo[3.3.1]nona-3,6-dien-4-yl)propanenitrile 2l 
(119 mg, 0.552 mmol, 7 %) as a red oil; Rf (1:3 acetone/hexane) 0.70; [α]
 –45.28 (c 1.00, CHCl3); 
νmax(neat) 2965, 2932, 2910, 2873, 2836, 1665, 1629, 1450, 1431, 1381, 1359, 1205, 1143, 1114, 
894, 798 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.36 (br s, 1H, CH-7), 2.72-2.65 (m, 2H, CH2-4β), 2.64-2.55 
(m, 2H, CH2-4α), 2.44 (br s, 1H, CH-5), 2.20-2.18 (m, 1H, CH2-9a), 2.16-2.14 (m, 1H, CH2-9b), 2.90-1.87 
(m, 1H, CH-1), 1.83 (dt, J = 12.0, 3.0 Hz, 1H, CH2-8a), 1.79 (d, J = 2.0 Hz, 3H, CH3-6α), 1.57 (dt, J = 12.0, 
3.0 Hz, 1H, CH2-8b), 1.17 (br s, 3H, CH3-2α), 1.12 (br s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 
164.9 (C-4), 134.1 (C-6), 123.0 (CH-7), 120.7 (CN), 51.3 (C-2), 40.3 (CH-5), 35.5 (CH2-4α), 34.0 (CH-1), 
31.9 (CH3-6α), 29.2 (CH2-9), 28.0 (CH3-2α), 25.9 (CH2-8), 24.2 (CH3-2α), 13.8 (CH2-4β); GC/MS Rt = 
6.455 min, m/z 216 (18 M), 177 (27), 136 (27), 121 (14), 93 (100), 77 (18 %).  HRMS (ES): C14H20N2 
calcd: 217.1699 [M+H]+; found: 217.1705 [M+H]+. 
4.1.6 Methyl 2-(2,2,6-trimethyl-3-azabicyclo[3.3.1]nona-3,6-dien-4-yl)acetate 2h 
(40 mg, 0.17 mmol, 2 %) as a yellow-green oil; Rf (CHCl3) 0.75; [α]
 –42.38 (c 1.00, CHCl3); νmax(neat) 
3259, 2960, 2943, 1649, 1595, 1229, 1139, 1049 cm-1; 1H NMR (500 MHz , CDCl3) δ 8.51 (s, 1H, OH), 
5.41 (s, 1H, CH-7), 4.75 (s, 1H, CH2-4αa), 4.64 (s, 1H, CH2-4αb), 4.38 (s, 1H, CH-4α), 3.63 (s, 3H, OCH3), 
2.47 (s, 1H, CH-5), 2.35-2.32 (m, 1H, CH2-8a), 2.23-2.22 (m, 2H, CH2-9), 2.10 (dt, J = 6.0, 3.0 Hz, 1H, 
CH2-8b), 1.94 (s, 1H, CH-1), 1.73 (br s, 3H, CH3-6α), 1.31 (br s, 3H, CH3-2α), 1.24 (br s, 3H, CH3-2α); 
13C 
NMR (125 MHz, CDCl3) δ 171.1 (C=O), 163.4 (C-4), 136.0 (C-6), 121.8 (CH-7), 108.3 (CH2-4α, keto), 
82.9 (CH-4α, enol), 54.9 (C-2), 50.2 (OCH3), 47.0 (CH-5), 35.5 (CH-1), 33.0 (CH3-2α), 30.8 (CH3-2α), 
27.7 (CH3-6α), 24.4 (CH2-9), 23.5 (CH2-8); GC/MS Rt = 6.643 min, m/z 235 (50 M), 220 (88), 204 (14), 
188 (100), 160 (10), 121 (11), 93 (17), 93 (14 %). HRMS (ES): C14H21NO2 calcd:  236.1645 [M+H]
+; 

















4.1.7 Ethyl 2-(2,2,6-trimethyl-3-azabicyclo[3.3.1]nona-3,6-dien-4-yl)acetate 2i 
(139 mg, 0.557 mmol, 7 %) as a yellow oil; Rf (1:9 ethyl acetate/ dichloromethane) 0.9; α]
 –123.92 
(c 1.00, CHCl3); νmax(neat) 3261, 2963, 2933, 1647, 1599, 1490, 1468, 1293, 1280, 1140, 1051, 782 
cm-1; 1H NMR (500 MHz, CDCl3) δ 8.28 (br s, 1H, OH), 5.40 (br s, 1H, CH-7), 4.73 (s, 1H, CH2-4αa), 4.63 
(s, 1H, CH2-4αb), 4.38 (s, 1H, CH-4α), 4.11-4.05 (m, 2H, CH2-4γ), 2.46 (br s, 1H, CH-5), 2.35-2.32 (m, 
1H, CH2-8a), 2.22-2.18 (m, 1H, CH2-8b), 2.10 (dt, J = 12.5, 3.0 Hz, 1H, CH2-9a), 1.93 (br s, 1H, CH-1), 
1.81-1.79 (m, 1H, CH2-9b), 1.74 (br s, 3H, CH3-6α), 1.30 (br s, 3H, CH3-2α), 1.25 (t, J = 7.5 Hz, 3H, CH3-
4δ), 1.24 (br s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 170.9 (C=O), 164.2 (C-4), 136.0 (C-6), 121.7 
(CH-7), 108.2 (CH2-4α, keto), 80.0 (CH-4α, enol), 58.6 (CH2-4γ), 55.2 (C-2), 40.1 (CH-5), 35.0 (CH-1), 
33.1 (CH3-2α), 28.9 (CH3-2α), 28.6 (CH2-8), 25.4 (CH2-9), 22.1 (CH3-6α), 15.0 (CH3-4δ); GC/MS Rt = 
17.968 min, m/z 249 (42 M), 234 (78), 204 (17), 188 (100), 162 (11), 93 (21 %). HRMS (ES): C15H23NO2 
calcd: 250.1802 [M+H]+; found: 250.1805 [M+H]+. 
4.1.8 (4Z)-4-(2-Ethoxy-2-hydroxy-ethylidene)-2,2,6-trimethyl-3-azabicyclo[3.3.1]nonan-6-ol 4i 
(56 mg, 0.21 mmol, 3 %) as a pale red solid; m.p. 92 °C, Rf (1:9 ethyl acetate/dichloromethane) 0.66; 
[α]
 –33.26 (c 1.00, CHCl3); νmax(neat) 3470, 3287, 2984, 2951, 2912, 2874, 1739, 1625, 1578, 1493, 
1454, 1365, 1342, 1330, 1272, 1230, 1145, 1133, 1102, 1052, 1029, 962, 907, 784, 714 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 8.50 (br s, 1H, OH), 4.35 (s, 1H, CH-4α), 4.04-4.14 (m, 2H, OCH2CH3), 2.24 (dt, J = 
13.0, 3.0 Hz, 1H, CH2-9a), 2.14 (br s, 1H, CH-5), 1.93 (dt, J = 13.0, 3.0 Hz, 1H, CH2-9b),  1.86-1.82 (m, 
2H, CH2-8a, CH2-7a), 1.79-1.72 (m, 1H, CH2-7b), 1.68 (br s, 1H, CH-1),  1.44-1.41 (dt, 1H, CH2-8b), 1.29 
(br s, 3H, CH3-2α), 1.28 (br s, 3H, CH3-2α), 1.27 (br s, 3H, CH3-6α), 1.26 (br s, 3H, OCH2CH3); 
13C NMR 
(125 MHz, CDCl3) δ 170.5 (C=O), 162.9 (C-4), 83.0 (CH-4α), 71.5 (C-6), 58.3 (OCH2CH3), 54.5 (C-2), 
46.6 (CH-5), 35.2 (CH-1) 32.9 (CH2-7), 32.6 (CH3-6α), 30.5 (CH3-2α), 27.3 (CH3-2α), 24.1 (CH2-8), 23.2 
(CH2-9), 14.6 (OCH2CH3); GC/MS Rt = 19.42 min, m/z 267 (52 M),  252 (100), 222 (26), 206 (70), 197 
(17), 182 (17), 148 (19), 96 (30), 43 (26 %). HRMS (ES): C15H25NO3 calcd: 268.1907 [M+H]
+; found: 
268.1898 [M+H]+. 
4.1.9 2,2,6-Trimethyl-4-[(E)-styryl]-3-azabicyclo[3.3.1]nona-3,6-diene 2f 
(1.067 g, 4.03 mmol, 53 %) as a yellow wax; Rf (0.5:9.5 ethanol/ethyl acetate) 0.69; [α]
	 –35.11 (c 
0.23, CHCl3); νmax(neat) 3321, 2965, 2929, 1607, 1451, 1331, 1255, 1212, 1186, 1153, 972, 752, 694 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.51 (d, J = 7.5 Hz, 2HAr, H-4d), 7.34 (t, J = 7.5, 2HAr, H-4e), 7.28 (t, 
J = 7.5 Hz, 1HAr, 4f), 7.16 (d, J = 16.5 Hz, 1H, H-4b), 6.88 (d, J = 16.5 Hz, 1H, H-4a), 5.38 (br s, 1H, CH-
7), 3.19 (br s, 1H, CH-5), 2.19-2.30 (m, 2H, CH2-8), 1.96 (br s, 1H, CH-1), 1.89 (dt, J = 2.5, 12.0 Hz, 1H, 
CH2-9a), 1.78 (br s, 3H, CH3-6α), 1.73 (dt, J = 2.5, 12.0 Hz, 1H, CH2-9b), 1.28 (br s, 3H, CH3-2α), 1.26 
(br s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 166.9 (C-4), 136.7 (C-4c), 135.4 (CH-4b), 135.1 (C-6), 
131.8 (CH-4a), 129.0 (CH-4d), 128.9 (CH-4f), 127.5 (CH-4e), 122.8 (CH2-8), 59.9 (C-2), 35.8 (CH-5), 
34.5 (CH-1), 32.5 (CH3-2α), 29.4 (CH2-8), 27.8 (CH3-2α), 25.8 (CH2-9), 24.1 (CH3-6α); GC/MS Rt = 6.10 
min, m/z 265 (50 M), 250 (14), 224 (7), 136 (21), 130 (18), 115 (14) 93 (100) 77 (18 %). HRMS (ES): 
C19H23N calcd: 266.1903 [M+H]
+; found: 266.1901 [M+H]+. 
4.1.10 4-(3,4-Dimethoxyphenyl)-2,2,6-trimethyl-3-azabicyclo[3.3.1]nona-3,6-diene 2g 
(948 mg, 3.17 mmol, 42 %) as a pale yellow wax; Rf (1:1 ethyl acetate/hexane) 0.46; [α]
 +66.64 (c 

















916, 771 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.51 (br s, 1H, CH-7), 7.24 (dd, J = 2.0, 8.5 Hz, 1H, Ar-4αf), 
6.88 (d, J = 2.0 Hz, 1H, Ar-4αb), 6.87 (d, J = 2.0 Hz, 1H, Ar-4αe), 4.40 (br s, 1H, CH-5), 3.96 (br s, 3H, 
OCH3), 3.94 (br s, 3H, OCH3), 2.01 (dt, J = 2.5 Hz, 13.5, 1H, CH2-9a), 1.96-1.93 (m, 1H, CH2-8a), 1.89-
1.87 (m, 1H, CH2-9b), 1.77-1.69 (m, 1H, CH-1), 1.72 (dt, J = 4.5, 14.0 Hz, 1H, CH2-8b), 1.42 (br s, 3H, 
CH3-2α), 1.28 (br s, 3H, CH3-2α) 1.14 (br s, 3H, CH3-6α); 
13C NMR (125 MHz, CDCl3) δ 167.2 (C-4), 
152.1 (C-4αa), 149.6 (C-4αc), 149.1 (C-4αd), 128.6 (C-6), 119.0 (C-4αf), 110.7 (CH-4αb), 110.5 (CH-
4αe), 110.3 (CH-7), 56.8 (C-2), 56.4 (OCH3), 56.4 (OCH3), 35.9 (CH-5), 34.7 (CH-1), 32.1 (CH3-2α), 27.7 
(CH3-6α), 26.9 (CH3-2α), 25.3 (CH2-8), 24.6 (CH2-9); GC/MS Rt = 22.22 min, m/z 299 (46 M), 164 (29), 
136 (35), 121 (14) 93 (100), 77 (15 %). HRMS (ES): C19H25NO2 calcd: 300.1958 [M+H]
+; found: 
300.1963 [M+H]+. 
4.1.11 (4-Bromophenyl)-(2,2,6-trimethyl-3-azabicyclo[3.3.1]nona-3,6-dien-4-yl)methanone 8j 
(372 mg, 1.08 mmol, 14 %) as a honey colour oil; Rf (1:3 ethyl acetate/hexane) 0.94; α]
 – 31.48 (c 
1.00, CHCl3); νmax(neat) 2957, 2929, 2870, 1665, 1655, 1587, 1460, 1384, 1272, 1231, 1071, 1013, 
899, 810, 756 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 8.5 Hz, 2H, Ar-4αb), 7.56 (d, J = 8.5 Hz, 
2H, Ar-4αc), 5.43 (br s, 1H, CH-7), 3.45 (br s, 1H, H-5), 2.32-2.25 (m, 2H, CH2-8), 1.99 (d, J = 3.0 Hz, 
1H, H-1), 1.91 (dt, J = 2.5, 12.0 Hz, 1H, CH2-9a), 1.77 (dt, J = 2.5, 12.0 Hz, 1H, CH2-9b), 1.52 (br s, 3H, 
CH3-6α), 1.32 (br s, 3H, CH3-2α), 1.26 (br s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 193.2 (C=O), 
166.5 (C-4), 134.9 (C-4αa), 134.5 (C-4αd), 132.6 (2C, C-4αb & C-4αf), 131.8 (2C, C-4αc & C-4αe), 
128.8 (C-6), 122.8 (CH-7), 61.3 (C-2), 35.1 (CH-5), 34.5 (CH-1), 31.3 (CH3-2α), 29.3 (CH2-8), 27.8 (CH3-
2α), 25.3 (CH2-9), 23.3 (CH3-6α); GC/MS Rt = 8.19 min, m/z 345 (29 M), 330 (54), 304 (18), 183 (27), 
155 (18), 93 (100), 77 (19 %). HRMS (ES): C18H20
79BrNO calcd: 346.0801 [M+H]+; found: 346.0803 
[M+H]+. 
4.1.12 (4-Nitrophenyl)-(2,2,6-trimethyl-3-azabicyclo[3.3.1]nona-3,6-dien-4-yl)methanone 8k 
(211 mg, 0.677 mmol, 12 %) as a deep red oil; Rf (1:3 ethyl acetate/hexane) 0.99; [α]

 –34.77 (c 
1.04, CHCl3); νmax(neat) 2967, 2933, 2870, 1672, 1603, 1525, 1460, 1346, 1272, 1231, 1110, 905, 856, 
810, 706 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.25 (dd, J = 7.5, 2H, Ar-4αc & Ar-4αe), 8.08 (dd, J = 7.0, 
2H, Ar-4αb & Ar-4αf), 5.45 (br s, 1H, H-7), 3.52 (br s, 1H, H-5), 2.31-2.33 (m, 2H, CH2-9), 2.01 (s, 1H, 
H1), 1.89 (dt, J = 3.0, 12.5 Hz, 1H, CH2-8a), 1.79 (dt, J = 3.0, 12.5 Hz, 1H, CH2-8b), 1.57 (br s, 3H, CH3-
6α), 1.33 (br s, 3H, CH3-2α) 1.26 (br s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 192.2 (C=O), 166.4 
(C-4), 150.3 (C-4αd), 141.3 (C-4αa), 134.8 (C-6), 132.1 (2C, CH-4αb & CH-4αf), 123.4 (2C, CH-4αc & 
CH-4αe), 123.0 (CH-7), 61.8 (C-2), 34.5 (CH-5), 34.4 (CH-1), 31.3 (CH3-2α), 29.3 (CH2-9), 27.7 (CH3-2α), 
25.3 (CH2-8), 23.3 (CH3-6α); GC/MS Rt = 23.44 min, m/z 312 (25M), 297 (50), 271 (24), 150 (24), 120 
(25), 93 (100), 77 (23 %). HRMS (ES): C18H20N2O3 calcd: 313.1547 [M+H]
+; found: 313.1554 [M+H]+. 
 2. Standard conditions for hydride reduction of cyclic imines  
 Compound 1a (0.20 g, 0.85 mmol) was dissolved in dry CH3OH (10 mL) in a 25 ml round 
bottom flask and fitted with a rubber septum and needle for ventilation of gases. The mixture was 
set to stir in an ice bath. To this mixture, NaBH4 (224 mg, 5.93 mmol, 7 mol equiv.) was added and 
left to stir at 0 °C for about 30 minutes, then at room temperature overnight. Water was added (5 

















The combined extracts were washed with saturated NaCl (20 mL) before drying over anhydrous 
Na2CO3 and the solvent removed under reduced pressure. The same procedure was adapted for the 
reduction of Imine-amides 1b, 1c, 1d and 1e and imine-alkenes 2a, 2d and 2e. 
4.2.1 N-((1S,4R,5R,6S)-2,2,4,6-Tetramethyl-3-azabicyclo[3.3.1]nonan-6-yl)acetamide 6a 
(195 mg, 0.819 mmol, 97 %) as a pale yellow solid; m.p. 100 °C; α]
 +18.30 (c 1.43, CHCl3); 
νmax(neat) 3307, 2954, 2932, 1638, 1544, 1439, 1378, 1292, 1261, 1116, 754, 733, 665 cm
-1. 1H NMR 
(500 MHz, CDCl3) δ 5.35 (s, 1H, NH), 3.37 (qd, J = 2.5, 7.5 Hz, 1H, CH-4), 2.46 (td, J = 5.5, 15.5 Hz, 1H, 
CH2-7a), 2.31 (s, 1H, CH-5), 1.94 (s, 3H, COCH3), 1.90-1.84 (m, 1H, CH2-8a), 1.82-1.80 (m, 2H, CH2-9), 
1.56-1.54 (m, 2H, CH2-7a and CH2-8b), 1.52 (s, 3H, CH3-6α), 1.30 (s, 1H, CH-1), 1.21 (d, J = 7.5 Hz, 3H, 
CH3- 4α), 1.19 (s, 3H, CH3-2α), 1.11 (s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 169.0 (C=O), 57.9 (C-
6), 53.3 (C-2), 51.3 (CH-4), 39.6 (CH-5), 35.6 (CH-1), 34.3 (CH2-9), 30.1 (CH2-7), 29.6 (CH3-2α), 28.0 
(CH3-6α), 27.4 (CH3-2α), 24.9 (CH2-8), 24.8 (COCH3), 23.1 (CH3-4α); GC/MS (EI) t = 12.56 min, m/z 
238 (20, M), 223 (100), 179 (26), 164 (26), 122 (26), 84 (46 %); HRMS (ES): C12H21N calcd: 239.2118 
[M+H]+; found: 239.2121 [M+H]+. 
4.2.2 (1S,5S)-2,2,4,6-Tetramethyl-3-azabicyclo[3.3.1]non-6-ene 7a 
(125 mg, 0.626 mmol, 56 %) as a red wax; Rf (3:7 MeOH/CH2Cl2) 0.47; [α]
 −15.71 (c 0.47, CHCl3); 
νmax(neat) 2957, 2923, 2886, 1734, 1599, 1458, 1379, 1227, 1160, 1126, 1083, 1035, 1011, 918, 824, 
800, 751 cm-1. 1H NMR (500 MHz, CDCl3) δ 5.57 (s, 1H, CH-7), 3.13 (qd J = 7.0, 2.5 Hz, 1H, CH-4), 2.20 
-2.17 (m, 1H, CH2-8s), 2.09-2.07 (m, 2H, CH2-8b & CH2-9a),  1.94 (d, J = 3.0 Hz, 1H, H-5), 1.71 (s, 3H, 
CH3-6α), 1.60 (dt, J = 3.5, 9.5 Hz 1H, CH2-9b), 1.43 (dt, J = 6.0, 3.0 Hz, 1H, CH-1), 1.21 (s, 3H, CH3-2), 
1.09 (s, 3H, CH3-2α), 0.98 (d, J = 7.0 Hz, 3H, CH3-4); 
13C NMR (125 MHz, CDCl3) δ 133.4 (C-6), 124.2 
(CH-7), 53.6 (C-2) 50.1 (CH-4), 39.7 (CH-5), 34.3 (CH-1), 29.8 (CH3-2α), 28.9 (CH2-9), 22.6 (CH2-8), 25.7 
(CH3-2α), 25.5 (CH3-6α), 21.7 (CH3-4α); GC/MS (EI) Rt = 11.09 min, m/z 179 (62 M), 164 (47), 136 (34), 
124 (43), 93 (100), 44 (32 %); HRMS (ES): C12H21N calcd: 180.1747 [M+H]
+; found: 180.1747 [M+H]+. 
4.2.3 N-(4-Ethyl-2,2,6-trimethyl-3-azabicyclo[3.3.1]nonan-6-yl)propanamide 6b 
(257 mg, 0.967 mmol, 42 %) as a white solid; m.p. 103 °C, Rf (1:3 ethyl acetate/hexane) 0.13; [α]

 
+26.80 (c 1.05, CHCl3); νmax(neat) 3302, 3069, 2957, 2933, 2877, 1637, 1544, 1460, 1432, 1382, 1361, 
1261, 1236, 1119, 1086, 974, 808 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.29 (br s, NH), 3.02 (ddd, J = 2.0, 
7.0, 2.5 Hz, 1H, CH-4), 2.53 (td, J = 4.5, 13.5, 1H, CH2-7a), 2.48 (br s, 1H, CH-5), 2.16 (qd, J = 1.0, 7.5 
Hz, 2H, COCH2CH3), 1.87-1.93 (m, 1H, CH2-8a), 1.83 (dt, J = 3.0, 13.5 Hz, 1H, CH2-9a), 1.77-1.76 (m, 
1H, CH2-9b),  1.74-1.66 (m, 1H, CH2-4αa), 1.52 (br s, 3H, CH3-6α), 1.50-1.48 (m, 1H, CH2-8b), 1.47-1.45 
(m, 1H, CH2-7b), 1.40-1.37 (m, 1H, CH2-4αb), 1.32-1.31 (m, 1H, CH-1), 1.18 (br s, 3H, CH3-2α), 1.14 (t, 
J = 7.5 Hz, 3H, COCH2 H3), 1.11 (br s, 3H, CH3-2α), 0.96 (t, J = 7.5 Hz, 3H, CH3-4β);
 13C NMR (125 MHz, 
CDCl3) δ 172.0 (C=O), 59.4 (CH-4), 57.9 (C-2), 53.6 (C-6), 38.1 (CH-5), 36.5 (CH-1), 35.1 (CH2-7), 31.2 
(COCH2CH3), 30.7 (CH2-9), 29.9 (CH3-2α), 29.7 (CH2-4α), 27.7 (CH3-2α), 27.5 (CH3-6α), 25.4 (CH2-8), 
12.7 (CH3-4β), 10.5 (COCH2CH3); GC/MS Rt = 7.22 min, m/z 266 (5M), 251 (25), 237 (100), 136 (25), 98 
(30), 58 (50 %). HRMS (ES): C16H30N2O calcd: 267.2431 [M+H]
+; found: 267.2430 [M+H]+. 

















(289 mg, 0.899 mmol, 82 %) as a pale yellow wax; α]
 +13.36 (c 1.00, CHCl3); νmax(neat) 3325, 3182, 
2958, 2931, 2874, 1642, 1541, 1508, 1459, 1438, 1381,1217, 1118, 752 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 5.29 (s, 1H, NH), 3.12-3.09 (m, 1H, H-4), 2.53 (td, J = 4.5, 13.5 Hz, 1H, CH2-7a), 2.46 (s, 1H, 
CH-5), 2.13 (t, J = 7.0 Hz, 2H, CH2-6αa), 1.92-1.89 (m, CH2-8a), 1.82-1.81 (m, 2H, CH2-4αa), 1.69-1.65 
(m, 1H, CH2-9a), 1.65-1.56 (m, 2H, CH2-6αb), 1.52 (br s, 3H, CH3-2α), 1.51-1.42 (m, 2H, CH2-8b & 
CH27b), 1.39-1.32 (m, 8H, CH2-9b, CH-1, CH2-4αb, CH2-4αc, CH2-6αc), 1.18 (br s, 3H, CH3-2α), 1.11 (br 
s, 3H, CH3-2α), 0.93 (t, J = 7.0 Hz, 3H, CH3-6αd), 0.90 (t, J = 6.5 Hz, 3H, CH3-4αd);
 13C NMR (125 MHz, 
CDCl3) δ 172.4 (C=O), 58.1 (C-2), 57.61 (CH-4), 53.6 (C-6), 38.6 (CH-5), 38.1 (CH2-6a), 36.8 (CH2-9), 
36.5 (CH-1), 35.1 (CH2-7), 30.8 (CH2-4αa), 30.7 (CH2-4αb), 29.9 (CH3-6), 28.4 (CH2-6αb), 27.7 (CH3-2α), 
27.7 (CH3-2α), 25.6 (CH2-8), 23.2 (CH2-4αc), 22.7 (CH2-6αc), 14.4 (CH3-4αd), 14.2 (CH3-6αd); GC/MS Rt 
= 22.53 min, m/z 322 (2 M), 307 (18), 265 (100), 222 (9), 206 (9), 164 (25), 126 (25), 86 (31 %). HRMS 
(ES): C20H38N2O calcd: 323.3057 [M+H]
+; found: 323.3037 [M+H]+. 
4.2.5 N-((1S,4S,5R,6S)-2,2,6-Trimethyl-4-phenyl-3-azabicyclo[3.3.1]nonan-6-yl)benzamide 6e 
(39 mg, 0.11 mmol, 94 %) as a pale yellow semi-solid; [α]
 +73.42 (c 1.00, CHCl3); νmax(neat) 3337, 
2969 , 2933, 1709, 1639, 1525 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.71 (d, J = 7.5 Hz, 2H, Ar-6γb & Ar-
6γf), 7.49 (d, J = 7.5 Hz, 2H, Ar-6γc & Ar-6γe), 7.46 (t, J = 7.5 Hz, 1H, Ar-6γd), 7.41 (t, J = 7.5 Hz, 2HAr, 
Ar-4αb & Ar-4αf), 7.32 (t, J = 7.5 Hz, 2H, Ar-4αc & Ar-4αe), 7.19 (t, J = 7.5 Hz, 1H, Ar-4αd), 5.94 (s, 1H, 
HNCO), 4.57 (br s, 1H, CH-5), 3.29 (s, 1H, NH), 2.80 (td, J = 5.0, 14.5 Hz, 1H, CH-4), 2.08 (s, 1H, CH-1), 
2.05-2.02 (m, 2H, CH2-7), 1.68-1.61 (m, 2H, CH2-8), 1.48-1.45 (m, 2H, CH2-9), 1.27 (s, 6H, 2CH3-2α). 
0.84 (s, 3H, CH3-6α); 
13C NMR (125 MHz, CDCl3) δ 167.2 (C=O), 166.4 (C-4αa), 145.4 (C-6γa), 131.5 
(2C, CH-6γb & CH-6γf), 131.0 (CH-4), 129.1 (2C, CH-6γc & CH-6γe), 128.7 (CH-6γd), 128.4 (2C, CH-4αb 
& CH-4αf), 127.1 (2C, CH-4αc & CH-4αe), 126.7 (CH-4αd), 58.8 (C-6), 53.4 (C-2), 36.0 (CH-5), 34.8 
(CH-1), 30.0 (CH2-7), 29.7 (CH3-6α), 27.3 (CH3-2α), 27.0 (CH3-2α), 25.1 (CH2-9), 24.9 (CH2-8). GC/MS 
(EI): Rt = 27.89 min, m/z 362 (38 M), 347 (34), 271 (13), 242 (18), 186 (25), 146 (33) 122 (18), 105 
(100), 91 (25), 77 (47 %); HRMS (ES): C24H31N2O calcd: 363.2436 [M+H]
+; found: 363.2324 [M+H]+. 
4.2.6 (4S,7S,8S)-2,2,6-Trimethyl-4-phenyl-3-azabicyclo[3.3.1]non-6-ene 7e 
(266 mg, 1.10 mmol, 80 %); Rf  (5:80:15, MeOH/EtOAc/n-hexane); [α]
 –20.84 (c 1.00, CHCl3); 
νmax(neat) 2961, 2922, 2883, 2836, 1600, 1439, 1382 cm
-1; 1H NMR (500 MHz, CDCl3) δ 7.26 (t, J = 7.5 
Hz, 2H, Ar-4αb & Ar-4αf), 7.21 (d, J = 7.5 Hz, 2H, Ar-4αc & Ar-4αe), 7.16 (t, J = 7.5 Hz, 1H, Ar-4αd), 
5.53 (s, 1H, CH-7), 4.26 (s, 1H, CH-5), 2.35 (d, J = 3.0 Hz, 1H, CH-4), 2.31-2.25 (m, 2H, CH2-9) 1.71 (dt, J 
= 3.0, 12.0 Hz, 2H, CH2-8), 1.64 (s, 1H, NH), 1.51 (t, J = 3.0 Hz, 1H, CH-1), 1.30 (s, 3H, CH3-2α), 1.22 (s, 
3H, CH3-6α), 0.87 (s, 3H, H3-2α) ppm; 
13C NMR (125MHz, CDCl3) δ 143.6 (C-6) 133.4 (C-4αa), 128.0 
(2C, CH-4αb & CH-4αf), 126.6 (CH-4αd), 125.7 (2C, CH-4αc & CH-4αe), 124.1 (CH-7), 57.1 (CH-5), 53.8 
(C-2), 42.6 (CH-4), 34.4 (CH-1), 30.1 (CH3-6α), 29.4 (CH2-9), 27.7 (CH2-8), 25.6 (CH2-2α), 24.2 (CH2-2α) 
ppm. GC/MS (EI): Rt = 17.75 min, m/z 241 (59 M), 226 (37), 146 (63), 106 (100), 93 (63), 79 (22 %). 
HRMS (ES): C17H24N calcd: 242.1903 [M+H]
+; found: 242.1901 [M+H]+. 
4.2.7 2-Chloro-N-((1S,4S,5R,6S)-4-(chloromethyl)-2,2,6-trimethyl-3-azabicyclo[3.3.1]nonan-6-
yl)acetamide 6d 
(139 mg, 0.45 mmol, 88 %) as a pale yellow solid; m.p. 88 °C;	[α]
 +76.42 (c 0.5, CHCl3); νmax(neat) 

















1. 1H NMR (500 MHz, CDCl3) δ 6.52 (s, 1H, NHCO), 3.97 (s, 2H, COCH2Cl), 3.78 (dd, J = 2.5, 10.5 Hz, 1H, 
CH2Cl-4αa), 3.66 (t, J = 10.0, 1H, CH2Cl-4αb), 3.46 (dt, J = 2.5, 10.5 Hz, 1H, CH-4), 2.65 (td, J = 5.0, 15.5 
Hz, 1H, CH2-7a), 2.54 (br s, 1H, CH-5), 1.98-1.94 (m, 1H, CH2-8a), 1.83 (q, J = 3.0 Hz, 2H, CH2-9), 1.56-
1.50 (m, 2H, CH2-7b & CH2-8b), 1.45 (s, 3H, CH3-6α), 1.38 (t, J = 3.0 Hz, 1H, CH-1), 1.21 (s, 3H, CH3-
2α), 1.16 (s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 164.4 (C=O), 59.4 (CH-4), 57.5 (C-6), 53.4 (C-2), 
50.5 (CH2Cl-4α), 43.1 (COCH2Cl), 38.9 (CH-5), 35.9 (CH-1), 34.2 (CH2-7), 30.0 (CH2-9), 29.4 (CH3-2α), 
27.4 (CH3-6α), 26.9 (CH3-2α), 24.8 (CH2-8); GC/MS (EI) Rt = 21.44 min, m/z 306 (9 M), 291 (100), 271 
(81), 257 (29), 121 (32), 58 (41 %); HRMS (ES): C14H24Cl2N2O calcd: 307.1266 [M+H]
+; found: 307.1266 
[M+H]+. 
4.2.8 4-(Chloromethyl)-2,2,6-trimethyl-3-azabicyclo[3.3.1]non-6-ene 7d 
(45 mg, 0.21 mmol, 85 %) as a yellow waxy liquid; Rf (diethyl ether) 0.98; α]
 –8.63 (c 0.24, CH2Cl2); 
νmax(neat) 3412, 3309, 2929, 2956, 1665, 1527, 1458, 1384, 1262, 1115, 1091, 1080, 804 cm
-1; 1H 
NMR (500 MHz, CDCl3) δ 5.61 (br s, 1H, CH-7), 3.37 (dd, J = 7.0, 10.5 Hz, 1H, CH2Cl-4αa), 3.28 (dd, J = 
2.5, 10.5 Hz, 1H, CH2Cl-4αb), 3.23 (td, J = 2.5, 2.5 Hz, 1H, CH-4), 2.29 (d, J = 2.0 Hz, 1H, CH-5), 2.28-
2.22 (m, 1H, CH2-9a), 2.10-2.03 (m, 2H, CH2-9b & CH2-8a), 1.71 (br s, 3H, CH3-6α), 1.64 (dt, J = 2.5, 
12.5 Hz, 1H, CH2-8b), 1.48-1.46 (m, 1H, CH-1), 1.21 (br s, 3H, CH3-2α), 1.11 (br s, 3H, CH3-2α); 
13C 
NMR (125 MHz, CDCl3) δ 164.8 (C-6), 132.5 (C-2), 125.9 (CH-7), 57.1 (CH-4), 48.0 (CH2Cl-4α), 36.5 
(CH-5), 35.2 (CH-1), 30.2 (CH3-2α), 29.0 (CH2-8), 28.1 (CH2-9), 26.1 (CH3-2α), 25.2 (CH3-6α); GC/MS Rt 
= 6.10 min, m/z 213 (28 M), 198 (66), 178 (43), 164 (25), 118 (50), 93 (100), 84 (31), 77 (18 %). HRMS 
(ES): C12H20ClN calcd: 214.1357 [M+H]
+; found: 214.1354 [M+H]+. 
 3. Polar bridged Ritter reaction conditions 
Sulfuric acid (18 M, 2 mL) was stirred in a flask fitted with a reflux condenser and a drying 
tube at 0 °C. To the reaction flask, the nitrile (53.4 mol, 7 mol equiv. of (–)-β-pinene) was added. A 
solution of (–)-β-pinene (1.2 mL, 7.62 mmol) in 10 mL glacial acetic acid was added dropwise to the 
reaction mixture, via the condenser. After 30 min the reaction was allowed to reach room 
temperature and left to stir for 24 h. The reaction was then quenched by the addition of 30 mL of 
water. The reaction mixture was then washed with CH2Cl2 to remove any neutral impurities before 
being basified with 4 M NaOH (until pH > 10). The reaction mix was then extracted with CHCl3 (2 X 15 
mL) and dried with Na2CO3. 
4.3.1 (2,2,4,6-Tetramethyl-3-azabicyclo[3.3.1]non-3-en-6-yl) acetate 5a 
(154 mg, 0.649 mmol, 9 %) as a pale yellow oily wax; Rf (1:3 ethyl acetate/hexane) 0.83; [α]
 +72.64 
(c 1.00, CHCl3); νmax(neat) 2949, 2927, 1732, 1649, 1627, 1458, 1367, 1245, 1220, 1200, 1157, 1099, 
1018 cm-1; 1H NMR (500 MHz, CDCl3) δ 3.12 (br s, 1H, CH-5), 2.06 (s, 3H, COCH3), 2.05 (s, 3H, CH3-4), 
1.83 (s, 1H, CH2-7a), 1.79-1.76 (m, 1H, CH2-7b), 1.75 (t, J = 2.5 Hz, 1H, CH2-8a), 1.74 (t, J = 3.5 Hz, 1H, 
CH2-9a), 1.73-1.70 (m, 2H, CH2-8b & CH2-9b), 1.63-1.62 (m, 1H, CH-1), 1.57 (s, 3H, CH3-6α), 1.27 (s, 
3H, CH3-2α), 1.16 (s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 170.8 (COCH3), 165.9 (C-4), 82.9 (C-6), 
58.5 (C-2), 42.2 (CH-5), 34.2 (CH-1), 33.0 (CH2-7), 31.9 (CH3-2α), 29.7 (COCH3), 26.6 (CH3-2α), 26.5 

















194 (100), 178 (64), 162 (22), 136 (68), 122 (61), 93 (78), 43 (49 %). HRMS (ES): C14H23NO2 calcd: 
238.1802 [M+H]+; found: 238.1805 [M+H]+. 
4.3.2 (4-Ethyl-2,2,6-trimethyl-3-azabicyclo[3.3.1]non-3-en-6-yl) acetate 5b 
(77 mg, 0.31 mmol, 4 %) as a yellow wax; Rf (1:3 hexane / diethyl ether) 0.46; α]
 +35.72 (c 1.00, 
CHCl3); νmax(neat) 2969, 2933, 2875, 1736, 1652, 1460, 1369, 1242, 1201, 1026, 823 cm
-1; 1H NMR 
(500 MHz, CDCl3) δ 3.19 (br s, 1H, CH-5), 2.67 (qd, J = 3.5, 7.5 Hz, 2H, CH2-4α), 2.05 (s, 3H, COCH3), 
1.82-1.78 (m, 3H, CH2-8, CH2-9a), 1.75-1.71 (m, 2H, CH2-7), 1.66-1.63 (m, 2H, CH-1, CH2-9b), 1.53 (s, 
3H, CH3-6α), 1.28 (s, 3H, CH3-2α), 1.14 (s, 3H, CH3-2α), 1.09 (t, J = 7.5 Hz, 3H, CH3-4β); 
13C NMR (125 
MHz, CDCl3) δ 170.9 (C=O), 170.6 (C-4), 83.2 (C-6), 58.3 (C-2), 40.0 (CH-5), 35.2 (CH2-4α), 34.5 (CH-1), 
32.9 (CH2-8), 32.0 (CH3-2α), 26.5 (CH3-2α), 26.2 (CH3-6α), 24.9 (CH2-7), 24.5 (CH2-9), 22.7 (COCH3), 
12.9 (CH3-4β); GC/MS Rt = 15.127 min, m/z 251 (57 M),236 (18), 208 (100), 192 (82), 176 (31), 150 
(27), 136 (81), 93  (42 %). HRMS (ES): C15H25NO2 calcd: 252.1958 [M+H]
+; found: 252.1956 [M+H]+. 
4.4 Amide deprotection of 5d 
A solution of compound 5d (194.4 mg, 0.64 mmol) dissolved in dry MeOH (10 mL), was 
added to a solution of thiourea (93.3 mg, 1.23 mmol, dissolved in dry MeOH (5 mL) and acetic acid (1 
mL). The reaction mixture was refluxed overnight (24 hr). The resulting suspension was cooled to 
room temperature before the water (10 mL) was added. The solution was then basified with 2 M 
NaOH until the pH was 14. The mixture was extracted with CHCl3 (2x15mL). The solvent was then 
removed under reduced pressure to give 9d (123.6 mg, 0.54 mmol). NMR and GC/MS analyses 
indicated that the product was pure and was used for the bioassay without further purification. 
4.5.1 (1S,4S,5R,6S)-4-(Chloromethyl)-2,2,6-trimethyl-3-azabicyclo[3.3.1]nonan-6-amine 9d 
(124 mg, 0.537 mmol, 85 %) as a yellow wax;	[α]

 +18.83 (c 1.63, MeOH); νmax(neat) 3321, 2923, 
2577, 2113, 1523, 1456, 1437, 1379m 1256, 1116, 720 cm-1; 1H NMR (500 MHz, CDCl3) δ 3.67-3.63 
(m, 2H, CH2-4α), 3.43 (dt, J = 2.5, 9.5 Hz, 1H, CH-4), 2.49 (td, J = 5.0, 14.0 Hz, 1H, CH2-7a), 2.12 (dt, J = 
3.0, 14.0 Hz, 1H, CH2-9a), 1.91-1.86 (m, 2H, CH2-8a & CH2-9b), 1.74 (dt, J = 5.0, 14.5 Hz, 1H, CH2-8b), 
1.69 (s, 1H, CH-5), 1.39-1.37 (m, 1H, CH-1), 1.37-1.34 (m, 1H, CH2-7b), 1.26 (s, 3H, CH3-6α), 1.20 (s, 
3H, CH3-2α), 1.14 (s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 54.8 (C-6), 60.3 (CH-4), 53.8 (C-2), 51.0 
(CH3-6α), 50.7 (CH2-4α), 44.2 (CH-5), 36.4 (CH-1), 35.1 (CH2-7), 29.9 (CH2-9), 29.5 (CH3-2α), 27.3 (CH3-
2α), 24.8 (CH2-8); GC/MS (EI) Rt = 16.64 min, m/z 230 (10), 215 (100), 195 (16), 118 (35), 70 (48 %); 
HRMS (ES): C12H23ClN2 calcd: 231.1623 [M+H]
+; found: 231.1618 [M+H]+. 
4.5 Reductive alkylation of 5a 
Compound 5a (100.0 mg, 0.42 mmol) was dissolved in MeCN (5 mL), to which sodium 
cyanoborohydride (502.0 mg, 7.99 mmol), 28 % formaldehyde solution (37 mL) and a few drops of 
acetic acid were added. The solution was stirred for 3 hours at room temperature. The solvent was 
removed via reduced pressure to give, both yellow and colourless crystals. These were triturated 
with hexane, the hexane then decanted and the remaining solid dried under reduced pressure to 

















4.4.1 N-((1S,4R,5R,6S)-2,2,3,4,6-Pentamethyl-3-azabicyclo[3.3.1]nonan-6-yl)acetamide 10a 
(48 mg, 0.19 mmol, 45 %) as a pale yellow solid; m.p. 165 °C; α]
 +13.89 (c 0.37, CHCl3); νmax(neat) 
3313,2981, 2960, 2943, 2881, 2846, 2802, 2789, 1638, 1545, 1465, 1439, 1380, 1370, 1310, 1299, 
1246, 1223, 1030, 958, 718 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.28 (s, 1H, NH), 2.89 (qd, J = 2.0, 7.0 
Hz, 1H, CH-4), 2.65 (td, J = 4.5, 14.0 Hz 1H, CH2-7a), 2.41 (br s, 1H, CH-5), 2.08 (s, 3H, NCH3), 1.96-
1.94 (m, 1H, CH2-8a), 1.94 (s, 3H, COCH3), 1.82 (qd, J = 3.0, 13.5 Hz, 1H, CH2-9a), 1.75 (dt, J = 3.0, 13.5 
Hz, 1H, CH2-9b), 1.52 (s, 3H, CH3-6α), 1.46 (dt, J = 4.5, 14.0 Hz, 1H, CH2-8b), 1.42-1.39 (m, 1H, CH2-
7b), 1.29 (br s, 1H, CH-1), 1.21 (d, J = 7.0 Hz, 3H, CH3-4α), 1.17 (s, 3H, CH3-2α), 0.98 (s, 3H, CH3-2α); 
13C NMR (125 MHz, CDCl3) δ 169.0 (C=O), 58.2 (CH-4), 57.5 (C-6), 57.4 (C-2), 41.8 (CH-5), 39.9 (CH-1), 
34.4 (CH2-9), 33.7 (CH3-3α), 30.0 (CH2-7), 28.5 (CH3-2α), 28.1 (CH3-6α), 25.0 (CH2-8), 24.5 (COCH3), 
22.5 (CH3-4α), 16.9 (CH3-2α); GC/MS (EI) Rt = 8.28 min, m/z 252 (4 M), 237 (100), 178 (22), 58 (37 %); 
HRMS (ES): C15H28N2O calcd: 253.2275 [M+H]
+; found: 253.2276 [M+H]+. 
4.6 DMAD addition of 1a 
Compound 1a (502.3 mg, 2.13 mmol) was dissolved in CHCl3 (15 mL) and then heated to 
reflux temperature. A solution of DMAD (309 mg, 2.18 mmol) dissolved in CHCl3 (5 mL) was added 
dropwise to the refluxing solution via the condenser. Once all the DMAD solution was added, the 
reaction was left to reflux for 4 hours. After which, the reaction was allowed to cool to room 
temperature before the solvent was removed under reduced pressure to obtain a dark yellow foam 
like the wax crude product (952 mg). The crude product was purified on an alumina column using a 
40 % n-hexane and 60 % ethyl acetate as the mobile phase to give pure 11 as a red-orange solid 
(458.6 mg, 1.21 mmol, 57 %). 
4.6.1 Dimethyl 2-((1S,5S,6S)-6-acetamido-2,2,6-trimethyl-4-methylene-3-azabicyclo[3.3.1]nonan-3-
yl)maleate 11 
(459 mg, 1.21 mmol, 57 %) as red orange solid; m.p. 50 °C; Rf (4:6 n-hexane/ethyl acetate) 0.40; 
[α]
 −464.16 (c 1.02, CHCl3); νmax(neat) 3309, 2950, 1715, 1654, 1585, 1542, 1433, 1370, 1340, 
1277, 1234, 1205, 1144, 989, 943, 840, 727 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.58 (s, 1H, H-3β) 5.26 
(s, 1H, NH), 4.61 (s, 1H, CH2-4αa), 4.44 (s, 1H, CH2-4αb), 3.73 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.34 
(br s, 1H, CH-5), 2.63 (td, J = 14.5, 5.0 Hz, CH2-7a), 2.05 (s, 3H, NCOCH3), 2.04-2.00 (m, 2H, CH2-8a & 
CH2-9a), 1.96 (s, 3H, CH3-2α), 1.90 (dt, J = 3.0, 10.5 Hz, CH2-9b), 1.62-1.55 (m, 1H, CH2-8b), 1.52-1.51 
(m, 1H, CH-1), 1.45 (s, 3H, CH3-6α), 1.40 (s, 3H, CH3-2α), 1.33 (dd, 1H, J = 14.5, 5.0 Hz, CH2-7b); 
13C 
NMR (125 MHz, CDCl3) δ 169.6 (C=O), 167.1 (C=O), 166.4 (C=O), 147.1 (C-4), 146.8 (C=CH), 106.7 
(C=CH2-4α), 60.5 (C-6), 56.1 (C-2), 52.4 (OCH3), 51.4 (OCH3), 41.4 (CH-1), 41.3 (CH-5), 31.0 (CH2-7), 
26.0 (COCH3), 25.9 (CH3-6α), 25.7 (CH2-9), 24.7 (CH3-2α), 24.3 (CH3-2α), 23.8 (CH2-8); GC/MS (EI) Rt = 
18.27 min, m/z 378 (18 M), 363 (18), 319 (100), 287 (79), 260 (67) 208 (18), 70 (31 %); HRMS (ES): 
C20H30N2O5 calcd: 379.2227 [M+H]
+; found: 379.2229 [M+H]+. 
4.7 X-ray Structure Analysis 

















Suitable single crystals of compounds (+)-6a, (+)-6b and 4i were selected under the 
polarizing microscope (Leica M165Z), were picked up on a MicroMount (MiTeGen, USA) consisting of 
a thin polymer tip with a wicking aperture. The X-ray diffraction measurements were carried out on 
a Bruker kappa-II CCD diffractometer at 150 K by using graphite-monochromated Mo-Kα radiation (λ 
= 0.710723 Å). The single crystals, mounted on the goniometer using cryo loops for intensity 
measurements, were coated with paraffin oil and then quickly transferred to the cold stream using 
an Oxford Cryo stream attachment. 
4.7.2 Solution and Refinement 
Symmetry-related absorption corrections using the program SADABS17 were applied, and the 
data were corrected for Lorentz and polarisation effects using Bruker APEX2 software.18 All 
structures were solved by direct methods and the full-matrix least-square refinements were carried 
out using SHELXL.19 The non-hydrogen atoms were refined anisotropically. The molecular graphics 
were generated using Olex220 and Mercury.21 Key crystallographic data and refinement details are 
presented in Table 5. 
Table 5. Crystal data and structure refinement for compounds 4i, (+)-6a, (+)-6b. 
 4i (+)-6a (+)-6b 
Crystal data 
Chemical formula 2(C15H25NO3) C14H26N2O C16H30N2O 
Mr 534.72 238.37 266.42 
Crystal system, 
space group 
Monoclinic, Cc Monoclinic, P21 Monoclinic, P21 
Temperature (K) 152 155 151 
a, b, c (Å) 9.9601 (8), 19.406 (2), 
7.8544 (6) 
8.4055 (5), 9.5712 (5), 9.4883 
(5) 
9.259 (2), 9.523 (2), 10.244 
(3) 
β (°) 98.746 (5) 112.922 (1) 115.841 (7) 
V (Å3) 1500.5 (2) 703.06 (7) 813.0 (4) 
Z 2 2 2 
Radiation type Mo Kα Mo Kα Mo Kα 
µ (mm-1) 0.08 0.07 0.07 
Crystal size (mm) 0.16 × 0.13 × 0.07 0.20 × 0.14 × 0.04 0.23 × 0.13 × 0.03 
 
Data collection 





(Bruker,2014/5) was used 
for absorption correction. 
wR2(int) was 0.1524 before 
and 0.0504 after correction. 
Multi-scan  
SADABS2007/4 
(Bruker,2007/4) was used for 
absorption correction. 
wR2(int) was 0.0482 before 
and 0.0371 after correction. 
Multi-scan  
SADABS2014/5 
(Bruker,2014/5) was used for 
absorption correction. 
wR2(int) was 0.1284 before 

















The Ratio of minimum to 
maximum transmission is 
0.8365. The λ/2 correction 
factor is 0.00150. 
The Ratio of minimum to 
maximum transmission is 
0.8847. The λ/2 correction 
factor is 0.0015. 
The Ratio of minimum to 
maximum transmission is 
0.8287. The λ/2 correction 
factor is 0.00150. 
 Tmin, Tmax 0.624, 0.746 0.660, 0.746 0.618, 0.746 
No. of measured, 
independent and 
 observed [I > 
2σ(I)] reflections 
11273, 3088, 2334   5997, 2937, 2874   5777, 2504, 1629   
Rint 0.056 0.025 0.061 
(sin θ/λ)max (Å-1) 0.640 0.639 0.641 
 
Refinement 
R[F2 > 2σ(F2)], 
wR(F2), S 
0.047,  0.113,  1.05 0.031,  0.083,  1.05 0.051,  0.121,  0.99 
No. of reflections 3088 2937 2504 
No. of 
parameters 
177 258 191 





All H-atom parameters 
refined 
H atoms treated by a mixture 
of independent and 
constrained refinement 
∆〉max, ∆〉min (e Å-3) 0.17, -0.17 0.22, -0.13 0.21, -0.22 
CCDC number 1485895 1485896 1485897 
 
5. Crystal structure data 
Crystallographic data (excluding structure factors) for the structures in this paper have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers 
1485895, 1485896 and 1485897. The data can be obtained free of charge via 
http://www.ccdc.cam.ac.uk or by e-mailing data_request@ccdc.cam.ac.uk, or by contacting The 
Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 
1223/336-033, Tel.: (+44) 1223/336-408. 
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